Closing 5 ideas | Jan 13, 2025
I am taking several off the list, first one being Angiodynamics (ANGO) written up here . It jumped in the past week on a slightly improved forecast...
301 Views
Actinver Research - Genomma Lab: Reaching Healthier Valuation Levels (Company Update)
After a stunning YTD performance (up 90.68% as of 12/9/24 vs MEXBOL 9.05% down), we continue to see solid upside ahead. Market conditions for most...
343 Views
Actinver Research - Genomma Lab 3Q24: Strong across the board (Quick View)
Revenues of P$5.1bn grew 15.9% YoY and were 6.8% above our estimates, supported by healthy growth across all regions. For a second consecutive...
262 Views
Kimberly-Clark De Mexico-A - Actinver Research - Supermarkets & HPC: 3Q24 Preview
We are updating our models ahead of 3Q24 Results; we downgrade Kimberly-Clark de Mexico to Market Perform (from Outperform), while lowering our PT...
384 Views
Actinver Research - Genomma Lab: 2Q24 – Strong results across the board (Earnings Review)
Better-than-expected 2Q24 results throughout the P&L. While we had already forecasted healthy profitability ahead, we are raising our...
287 Views